PUBLISHER: The Business Research Company | PRODUCT CODE: 1946570
PUBLISHER: The Business Research Company | PRODUCT CODE: 1946570
Mucosal atomization devices are designed to administer medication through the nostrils, ensuring reliable topical solution atomization across the nasal and oropharyngeal mucous membranes. These devices are particularly effective in delivering atomized medication to mucosal surfaces in the nasal, oral, laryngeal, tracheal, and lung regions.
The primary types of mucosal atomization devices include nasal atomization devices, fibre-optic atomization devices, laryngotracheal atomization devices, and bottle atomizer devices. Nasal atomization devices provide a painless and safe method for swiftly delivering fast-acting drugs that efficiently penetrate mucosal membranes and enter the bloodstream. Various mucosal atomization device technologies include gas-propelled atomization devices and electrical atomization devices. These devices find application in diverse healthcare settings, including hospitals, ambulatory surgical centers, and specialized clinics.
Tariffs are impacting the mucosal atomization devices market by increasing costs of imported medical-grade plastics, precision nozzles, pumps, and electronic components used in atomization systems. Healthcare providers in North America and Europe are most affected due to reliance on imported device components, while Asia-Pacific faces higher production costs. These tariffs are increasing device prices and procurement costs. However, they are also driving local manufacturing, regional supplier development, and innovation in simplified and disposable atomization devices.
The mucosal atomization devices market research report is one of a series of new reports from The Business Research Company that provides mucosal atomization devices market statistics, including mucosal atomization devices industry global market size, regional shares, competitors with a mucosal atomization devices market share, detailed mucosal atomization devices market segments, market trends and opportunities, and any further data you may need to thrive in the mucosal atomization devices industry. This mucosal atomization devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The mucosal atomization devices market size has grown rapidly in recent years. It will grow from $0.92 billion in 2025 to $1.02 billion in 2026 at a compound annual growth rate (CAGR) of 10.9%. The growth in the historic period can be attributed to increasing use of nasal drug delivery methods, rising emergency medical interventions, growth of outpatient treatment settings, availability of atomization-based therapies, increased clinical awareness of mucosal delivery.
The mucosal atomization devices market size is expected to see rapid growth in the next few years. It will grow to $1.52 billion in 2030 at a compound annual growth rate (CAGR) of 10.5%. The growth in the forecast period can be attributed to increasing demand for non-invasive drug administration, rising adoption in emergency and anesthesia care, expansion of home healthcare usage, growing focus on infection control, increasing development of portable medical delivery devices. Major trends in the forecast period include increasing adoption of needle-free drug delivery devices, rising demand for rapid-acting emergency medications, growing use of single-use atomization devices, expansion of portable atomization solutions, enhanced focus on patient comfort and safety.
The increasing prevalence of allergic rhinitis is anticipated to support the growth of the mucosal atomization devices market in the coming years. Allergic rhinitis is an inflammatory disorder of the nasal passages triggered by an immune response to airborne allergens such as pollen, dust mites, and animal dander. Its rising incidence is primarily associated with worsening air quality and higher exposure to environmental allergens, as rapid urbanization and industrial activity lead to elevated levels of particulate matter and pollutants that provoke and intensify allergic reactions in vulnerable populations. As the number of affected individuals grows, demand increases for effective nasal drug delivery solutions that can deliver medication quickly and directly to the nasal mucosa, offering rapid relief from symptoms including nasal congestion, sneezing, and inflammation. For example, in January 2024, according to the UK Health Security Agency, consultation rates for allergic rhinitis rose significantly during week 23, corresponding with high grass pollen levels and warmer weather conditions. The highest consultation rates were recorded among individuals aged 5-14 years and 15-44 years, with rates also exceeding seasonal baseline levels in London, the South East, and the South West regions. As a result, the growing burden of allergic rhinitis is contributing to the expansion of the mucosal atomization devices market.
Major companies in the mucosal atomization device market are concentrating on developing technological advancements such as metal-free nasal spray pumps to enhance the patient experience. For example, in January 2023, Aptar Pharma, a US-based pharmaceutical company, introduced the APF Futurity. This metal-free, multidose nasal spray pump is designed for delivering nasal saline and similar over-the-counter (OTC) formulations. The APF Futurity is Aptar Pharma's first highly recyclable nasal spray pump, having received a Class AA certification from cyclos-HTP for recycling in Europe. Constructed from polyolefin materials without any metal components or recycling disruptors, the APF Futurity reduces separation efforts in recycling streams and supports the production of higher quality recyclates.
In October 2024, Aptar Pharma Inc., a United States-based healthcare technology company, acquired all device technology assets of SipNose Nasal Delivery Systems Ltd. for an undisclosed consideration. Through this acquisition, Aptar Pharma sought to enhance its intranasal drug delivery portfolio, with particular emphasis on strengthening its nose-to-brain delivery capabilities by incorporating SipNose's advanced technologies. The transaction is expected to accelerate the development of innovative therapies for central nervous system and systemic conditions, reinforce Aptar Pharma's technological leadership in precision nasal delivery, and improve its competitive positioning in the global pharmaceutical drug delivery landscape. SipNose Nasal Delivery Systems Ltd. is an Israel-based medical technology company focused on the development of specialized intranasal delivery platforms.
Major companies operating in the mucosal atomization devices market are Teleflex Incorporated, Cook Medical LLC, Pulmodyne Inc., Life-Assist Inc., Vyaire Medical Inc., Mercury Medical, SunMed LLC, Salter Labs, Armstrong Medical Industries Inc., VBM Medizintechnik GmbH, Intersurgical Ltd., Flexicare Medical Limited, Medovations Inc., Atom Medical Corporation, BLS Systems Limited, Dali Medical Devices Co. Ltd., Trudell Medical International, PARI GmbH, Omron Healthcare Inc., Drive Medical Holdings LLC, Laerdal Medical AS
North America was the largest region in the mucosal atomization devices market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the mucosal atomization devices market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the mucosal atomization devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain
The mucosal atomization devices market consists of sales of 3cc Syringe and VetJet. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Mucosal Atomization Devices Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses mucosal atomization devices market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for mucosal atomization devices ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The mucosal atomization devices market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.